Switch Maintenance Endocrine Therapy Plus Bevacizumab After Bevacizumab Plus Paclitaxel in ER+/HER2− Advanced or Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial
Lancet Oncol 2022 Apr 08;[EPub Ahead of Print], S Saji, N Taira, M Kitada, T Takano, M Takada, T Ohtake, T Toyama, Y Kikawa, Y Hasegawa, T Fujisawa, M Kashiwaba, T Ishida, R Nakamura, Y Yamamoto, U Toh, H Iwata, N Masuda, S Morita, S Ohno, M ToiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.